Henrik Bengtsson
Research Subjects
Research Interests
Henrik Bengtsson has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Tinna Björk Aradóttir
Novo Nordisk A/S, Bagsværd, Denmark
2 shared publications - Alican Özkan
Wyss Institute for Biologically Inspired Engineering at Harvard University, Boston, MA, USA
1 shared publication - Anne Kaas
Novo Nordisk A/S, Bagsværd, Denmark
1 shared publication - Arash Naziripour
Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02215, USA
1 shared publication - Badrinath Jagannath
Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02215, USA
1 shared publication - Dimitri Boiroux
Technical University of Denmark,Department of Applied Mathematics and Computer Science,Kgs. Lyngby,Denmark,DK-2800
1 shared publication
Latest Publications
- Open Access
- 6 March 2025
- Published by MDPI AG in Biosensors
- Vol. 15 (3) , 171
An Antimicrobial and Antifibrotic Coating for Implantable Biosensors
Biofouling and foreign body responses have deleterious effects on the functionality and longevity of implantable biosensors, seriously impeding their implementation for long-term monitoring. Here, we describe a nanocomposite coating composed of a cross-linked lattice of bovine serum albumin and pentaamine-functionalized reduced graphene that is covalently coupled to antibody ligands for analyte detection as well as antibiotic drugs (gentamicin or ceftriaxone), which actively combats biofouling while retaining high electroconductivity and excellent electrochemical immunosensor behavior. Sensors overlaid with this coating inhibit the proliferation of Pseudomonas aeruginosa bacteria and adhesion of primary human fibroblasts while not having any significant effects on fibroblast viability or on the immune function of primary human monocytes. Under these conditions, the sensor maintains its electrochemical stability for at least 3 weeks after exposure to soluble proteins that interfere with the activity of uncoated sensors. Proof-of-concept for the coating’s applicability is demonstrated by integrating the antimicrobial coating within an immunosensor and demonstrating the detection of cytokines in both culture medium and complex human plasma. This new coating technology holds the potential to substantially increase the lifespan of implanted biosensors and widen their application areas, potentially enabling continuous monitoring of analytes in complex biofluids for weeks in vivo.
- 6 March 2025
- Published by MDPI AG in Biosensors
- Vol. 15 (3) , 171
Open AccessAn Antimicrobial and Antifibrotic Coating for Implantable Biosensors
Biofouling and foreign body responses have deleterious effects on the functionality and longevity of implantable biosensors, seriously impeding their implementation for long-term monitoring. Here, we describe a nanocomposite coating composed of a cross-linked lattice of bovine serum albumin and pentaamine-functionalized reduced graphene that is covalently coupled to antibody ligands for analyte detection as well as antibiotic drugs (gentamicin or ceftriaxone), which actively combats biofouling while retaining high electroconductivity and excellent electrochemical immunosensor behavior. Sensors overlaid with this coating inhibit the proliferation of Pseudomonas aeruginosa bacteria and adhesion of primary human fibroblasts while not having any significant effects on fibroblast viability or on the immune function of primary human monocytes. Under these conditions, the sensor maintains its electrochemical stability for at least 3 weeks after exposure to soluble proteins that interfere with the activity of uncoated sensors. Proof-of-concept for the coating’s applicability is demonstrated by integrating the antimicrobial coating within an immunosensor and demonstrating the detection of cytokines in both culture medium and complex human plasma. This new coating technology holds the potential to substantially increase the lifespan of implanted biosensors and widen their application areas, potentially enabling continuous monitoring of analytes in complex biofluids for weeks in vivo.
- Open Access
- 7 December 2022
- Published by Springer Nature in Trials
- Vol. 23 (1) , 1-9
The Diabetes teleMonitoring of patients in insulin Therapy (DiaMonT) trial: study protocol for a randomized controlled trial
Background: The effect of telemedicine solutions in diabetes remains inconclusive. However, telemedicine studies have shown a positive trend in regards to glycemic control. The telemedicine interventions that facilitate adjustment of medication seems to improve glycemic control more effectively. Hence, it is recommended that future telemedicine studies for patients with diabetes include patient-specific suggestions for changes in medicine. Hence, the aim of the trial is to explore the effect of telemonitoring in patients with type 2 diabetes (T2D) on insulin therapy. Methods: The trial is an open-label randomized controlled trial with a trial period of 3 months conducted in two sites in Denmark. Patients with T2D on insulin therapy will be randomized (1:1) to a telemonitoring group (intervention) or a usual care group (control). The telemonitoring group will use a continuous glucose monitor (CGM), an insulin pen, an activity tracker, and smartphone applications throughout the trial. Hospital staff will monitor the telemonitoring group and contact the subjects by telephone repeatedly throughout the trial period. The usual care group will use a blinded CGM the first and last 20 days of the trial and will use a blinded insulin pen for the entire period. The primary endpoint will be changed from baseline in CGM time in range (3.9–10.0 mmol/L) 3 months after randomization. Secondary endpoints include change from baseline in glycated hemoglobin (HbA1c), total daily dose, time above range, and time below range 3 months after randomization. Exploratory endpoints include health-related quality of life, diabetes-related quality of life, etc. Discussion: The DiaMonT trial will test a telemonitoring setup including various devices. Such a setup may be criticized, because it is impossible to determine which element(s) add to the potential effect. However, it is not possible and counterproductive to test the elements individually, since it is the full telemedicine setup that is being evaluated. The DiaMonT trial is the first Danish trial to explore the effect of telemonitoring on patients on insulin therapy. Thus, the DiaMonT trial has the potential to form the basis for the implementation of telemedicine for patients with T2D in Denmark. Trial registration: ClinicalTrials.gov NCT04981808. Registered on 8 June 2021.
- 7 December 2022
- Published by Springer Nature in Trials
- Vol. 23 (1) , 1-9
Open AccessThe Diabetes teleMonitoring of patients in insulin Therapy (DiaMonT) trial: study protocol for a randomized controlled trial
Background: The effect of telemedicine solutions in diabetes remains inconclusive. However, telemedicine studies have shown a positive trend in regards to glycemic control. The telemedicine interventions that facilitate adjustment of medication seems to improve glycemic control more effectively. Hence, it is recommended that future telemedicine studies for patients with diabetes include patient-specific suggestions for changes in medicine. Hence, the aim of the trial is to explore the effect of telemonitoring in patients with type 2 diabetes (T2D) on insulin therapy. Methods: The trial is an open-label randomized controlled trial with a trial period of 3 months conducted in two sites in Denmark. Patients with T2D on insulin therapy will be randomized (1:1) to a telemonitoring group (intervention) or a usual care group (control). The telemonitoring group will use a continuous glucose monitor (CGM), an insulin pen, an activity tracker, and smartphone applications throughout the trial. Hospital staff will monitor the telemonitoring group and contact the subjects by telephone repeatedly throughout the trial period. The usual care group will use a blinded CGM the first and last 20 days of the trial and will use a blinded insulin pen for the entire period. The primary endpoint will be changed from baseline in CGM time in range (3.9–10.0 mmol/L) 3 months after randomization. Secondary endpoints include change from baseline in glycated hemoglobin (HbA1c), total daily dose, time above range, and time below range 3 months after randomization. Exploratory endpoints include health-related quality of life, diabetes-related quality of life, etc. Discussion: The DiaMonT trial will test a telemonitoring setup including various devices. Such a setup may be criticized, because it is impossible to determine which element(s) add to the potential effect. However, it is not possible and counterproductive to test the elements individually, since it is the full telemedicine setup that is being evaluated. The DiaMonT trial is the first Danish trial to explore the effect of telemonitoring on patients on insulin therapy. Thus, the DiaMonT trial has the potential to form the basis for the implementation of telemedicine for patients with T2D in Denmark. Trial registration: ClinicalTrials.gov NCT04981808. Registered on 8 June 2021.
- Open Access
Estimating a Personalized Basal Insulin Dose from Short-Term Closed-Loop Data in Type 2 Diabetes
In type 2 diabetes (T2D) treatment, finding a safe and effective basal insulin dose is a challenge. The dose-response is highly individual and to ensure safety, people with T2D titrate by slowly increasing the daily insulin dose to meet treatment targets. This titration can take months. To ease and accelerate the process, we use short-term artificial pancreas (AP) treatment tailored for initial titration and apply it as a diagnostic tool. Specifically, we present a method to automatically estimate a personalized daily dose of basal insulin from closed-loop data collected with an AP. Based on AP-data from a stochastic simulation model, we employ the continuous-discrete extended Kalman filter and a maximum likelihood approach to estimate parameters in a simple dose-response model for 100 virtual people. With the identified model, we compute a daily dose of basal insulin to meet treatment targets for each individual. We test the personalized dose and evaluate the treatment outcomes against clinical reference values. In the tested simulation setup, the proposed method is feasible. However, more extensive tests will reveal whether it can be deemed safe for clinical implementation.
Open AccessEstimating a Personalized Basal Insulin Dose from Short-Term Closed-Loop Data in Type 2 Diabetes
In type 2 diabetes (T2D) treatment, finding a safe and effective basal insulin dose is a challenge. The dose-response is highly individual and to ensure safety, people with T2D titrate by slowly increasing the daily insulin dose to meet treatment targets. This titration can take months. To ease and accelerate the process, we use short-term artificial pancreas (AP) treatment tailored for initial titration and apply it as a diagnostic tool. Specifically, we present a method to automatically estimate a personalized daily dose of basal insulin from closed-loop data collected with an AP. Based on AP-data from a stochastic simulation model, we employ the continuous-discrete extended Kalman filter and a maximum likelihood approach to estimate parameters in a simple dose-response model for 100 virtual people. With the identified model, we compute a daily dose of basal insulin to meet treatment targets for each individual. We test the personalized dose and evaluate the treatment outcomes against clinical reference values. In the tested simulation setup, the proposed method is feasible. However, more extensive tests will reveal whether it can be deemed safe for clinical implementation.
- 8 October 2018
- Published by Elsevier in IFAC-PapersOnLine
- Vol. 51 (15) , 551-556
Modelling of glucose-insulin dynamics from low sampled data
- 8 October 2018
- Published by Elsevier in IFAC-PapersOnLine
- Vol. 51 (15) , 551-556
Modelling of glucose-insulin dynamics from low sampled data